Roche's group sales grew by 6% at constant exchange rates, driven by high demand for newer medicines and diagnostic solutions. The Pharmaceuticals Division saw an 8% increase in sales, led by strong demand for Phesgo, Vabysmo, Xolair, Hemlibra, and Xofluza. The Diagnostics Division's sales remained stable, with high demand across products and regions offsetting the impact of healthcare pricing reforms in China. Roche achieved several regulatory milestones, including US approval for Evrysdi and Susvimo, and EU approval for Columvi. The company also announced plans to invest $50 billion in pharmaceuticals and diagnostics in the US over the next five years, creating over 12,000 new jobs. Roche's CEO, Thomas Schinecker, expressed confidence in the company's positive momentum and confirmed its full-year outlook. The company expects an increase in group sales in the mid-single digit range and core earnings per share to develop in the high single digit range. Roche also unveiled its novel sequencing by expansion technology, a new class of next-generation sequencing. The company's collaboration with Zealand Pharma will co-develop and co-commercialize an amylin analogue for weight loss. Finally, Roche's investment in the US will expand its already strong footprint, with over 25,000 employees, 15 R&D sites, and 13 manufacturing sites.